Paratek Pharmaceuticals Inc logo

Paratek Pharmaceuticals Inc

0
FRA:N4CN (USA)  
€ 2.02 (0%) Sep 21
At Loss
Market Cap:
€ 120.01M ($ 130.52M)
Enterprise V:
€ 323.81M ($ 352.15M)
Volume:
-
Avg Vol (2M):
-
Trade In:

Business Description

Paratek Pharmaceuticals Inc logo
Paratek Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
ISIN : US6993743029
Description
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Name Current Vs Industry Vs History
Name Current Vs Industry Vs History
Name Current Vs Industry Vs History
6-1 Month Momentum % 63.48
12-1 Month Momentum % -17.64

Liquidity Ratio

Name Current Vs Industry Vs History

Dividend & Buy Back

Name Current Vs Industry Vs History
Name Current Vs Industry Vs History
FCF Margin % -14.36
Name Current Vs Industry Vs History
EV-to-Forward-Revenue 1.48

Financials (Next Earnings Date:2025-03-15 Est.)

FRA:N4CN's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Paratek Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 159.094
EPS (TTM) (€) -1.055
Beta 0
Volatility % 98.73
14-Day RSI 0
14-Day ATR (€) 0.041
20-Day SMA (€) 0
12-1 Month Momentum % -17.64
52-Week Range (€) 1.194 - 3.65
Shares Outstanding (Mil) 57.32

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 0
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Paratek Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Paratek Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Paratek Pharmaceuticals Inc Frequently Asked Questions

What is Paratek Pharmaceuticals Inc(FRA:N4CN)'s stock price today?
The current price of FRA:N4CN is €2.02. The 52 week high of FRA:N4CN is €3.65 and 52 week low is €1.19.
When is next earnings date of Paratek Pharmaceuticals Inc(FRA:N4CN)?
The next earnings date of Paratek Pharmaceuticals Inc(FRA:N4CN) is 2025-03-15 Est..
Does Paratek Pharmaceuticals Inc(FRA:N4CN) pay dividends? If so, how much?
Paratek Pharmaceuticals Inc(FRA:N4CN) does not pay dividend.

Press Release

Subject Date
No Press Release